和誉-B(02256.HK)：FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格，用于治疗肝细胞癌

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its self-developed selective oral small molecule FGFR4 inhibitor, Irpagratinib (ABSK-011), for the treatment of hepatocellular carcinoma (HCC) [1] Group 1 - The orphan drug designation will support the clinical development, registration, and commercialization process of Irpagratinib in Europe [1] - Irpagratinib is currently undergoing clinical studies in multiple locations worldwide [1]